Currently autoantibodies that bind specifically to the P/Q-type VGCC (Cav2.1) are detected in over 90% of patients by a radioimmunoprecipitation assay using the neurotoxin -conotoxin MVIIC (-CmTx MVIIC), but these assays are not available in many centres worldwide.